|

Irinotecan Liposome Clinical Trials

7 actively recruiting trials

▼ -1 trial since May 2026

Also known as: Irinotecan liposome injection

Pipeline

Phase 2: 5

Top Sponsors

  • Fudan University2
  • West China Hospital1
  • Sun Yat-sen University1
  • Peking University1
  • Ming-Yuan Chen1

Indications

  • Cancer7
  • Recurrent or Metastatic Nasopharyngeal Carcinoma2
  • Pancreatic Cancer Metastatic to Liver1
  • Small Cell Lung Cancer Recurrent1
  • Pancreatic Cancer1

Other7 trials

Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety
Phase 2
Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer
Phase 2
Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
Phase 2
Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC
N/A
Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC
Phase 2
Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer
Phase 2
Real-world Study to Evaluate the Efficacy and Safety of Liposome Irinotecan

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.